Heads up!
We’ve moved some things around. Take a quick tour to learn what has changed.
Take the tour
No thanks!
6-Deoxyerythronolide B
Identification
- Name
- 6-Deoxyerythronolide B
- Accession Number
- DB04070
- Description
- Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for 6-Deoxyerythronolide B (DB04070)
- Weight
- Average: 386.5228
Monoisotopic: 386.266838948 - Chemical Formula
- C21H38O6
- Synonyms
- Not Available
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
Target Actions Organism U6-deoxyerythronolide B hydroxylase Not Available Saccharopolyspora erythraea (strain NRRL 23338) - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbiraterone The metabolism of Abiraterone can be decreased when combined with 6-Deoxyerythronolide B. Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with 6-Deoxyerythronolide B. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with 6-Deoxyerythronolide B. Acetyldigitoxin The serum concentration of Acetyldigitoxin can be increased when it is combined with 6-Deoxyerythronolide B. Albendazole The metabolism of Albendazole can be decreased when combined with 6-Deoxyerythronolide B. Alectinib The metabolism of Alectinib can be decreased when combined with 6-Deoxyerythronolide B. Alfentanil The serum concentration of Alfentanil can be increased when it is combined with 6-Deoxyerythronolide B. Alfuzosin The metabolism of Alfuzosin can be decreased when combined with 6-Deoxyerythronolide B. Alpelisib The metabolism of Alpelisib can be decreased when combined with 6-Deoxyerythronolide B. Alprazolam The metabolism of Alprazolam can be decreased when combined with 6-Deoxyerythronolide B. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Products
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as macrolides and analogues. These are organic compounds containing a lactone ring of at least twelve members.
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- Macrolides and analogues
- Sub Class
- Not Available
- Direct Parent
- Macrolides and analogues
- Alternative Parents
- Secondary alcohols / Lactones / Cyclic ketones / Carboxylic acid esters / Polyols / Oxacyclic compounds / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives
- Substituents
- Alcohol / Aliphatic heteromonocyclic compound / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Cyclic ketone / Hydrocarbon derivative / Ketone / Lactone / Macrolide
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- erythronolide (CHEBI:16089) / Macrolides and lactone polyketides (C03240) / Macrolides and lactone polyketides (LMPK04000002)
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- HQZOLNNEQAKEHT-IBBGRPSASA-N
- InChI
- InChI=1S/C21H38O6/c1-8-16-12(4)19(24)13(5)17(22)10(2)9-11(3)18(23)14(6)20(25)15(7)21(26)27-16/h10-16,18-20,23-25H,8-9H2,1-7H3/t10-,11+,12+,13+,14-,15-,16-,18+,19+,20+/m1/s1
- IUPAC Name
- (3R,4S,5R,6S,7S,9R,11R,12S,13R,14R)-14-ethyl-4,6,12-trihydroxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
- SMILES
- [H][C@@]1(C)C[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C(=O)O[C@]([H])(CC)[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C1=O
References
- Synthesis Reference
Robert McDaniel, "Production of 8,8a-dihydroxy-6-deoxyerythronolide B." U.S. Patent US20010034046, issued October 25, 2001.
US20010034046- General References
- Not Available
- External Links
- PDB Entries
- 1jio / 1oxa / 1z8o / 1z8p / 1z8q / 5mns / 5mnv
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.12 mg/mL ALOGPS logP 1.8 ALOGPS logP 2.87 ChemAxon logS -2.5 ALOGPS pKa (Strongest Acidic) 14 ChemAxon pKa (Strongest Basic) -3 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 104.06 Å2 ChemAxon Rotatable Bond Count 1 ChemAxon Refractivity 102.94 m3·mol-1 ChemAxon Polarizability 42.94 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.8891 Blood Brain Barrier + 0.8618 Caco-2 permeable - 0.5356 P-glycoprotein substrate Substrate 0.5407 P-glycoprotein inhibitor I Non-inhibitor 0.8554 P-glycoprotein inhibitor II Non-inhibitor 0.7101 Renal organic cation transporter Non-inhibitor 0.9497 CYP450 2C9 substrate Non-substrate 0.8196 CYP450 2D6 substrate Non-substrate 0.8539 CYP450 3A4 substrate Non-substrate 0.5317 CYP450 1A2 substrate Non-inhibitor 0.8867 CYP450 2C9 inhibitor Non-inhibitor 0.8888 CYP450 2D6 inhibitor Non-inhibitor 0.9394 CYP450 2C19 inhibitor Non-inhibitor 0.8459 CYP450 3A4 inhibitor Non-inhibitor 0.5415 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9514 Ames test Non AMES toxic 0.6607 Carcinogenicity Non-carcinogens 0.8856 Biodegradation Not ready biodegradable 0.8668 Rat acute toxicity 2.6539 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9771 hERG inhibition (predictor II) Non-inhibitor 0.9444
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
- Kind
- Protein
- Organism
- Saccharopolyspora erythraea (strain NRRL 23338)
- Pharmacological action
- Unknown
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
- Specific Function
- Catalyzes the NADPH-dependent conversion of 6-deoxyerythronolide B (6-DEB) to erythronolide B (EB) by the insertion of an oxygen at the 6S position of 6-DEB. Requires the participation of a ferredo...
- Gene Name
- eryF
- Uniprot ID
- Q00441
- Uniprot Name
- 6-deoxyerythronolide B hydroxylase
- Molecular Weight
- 45098.685 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Inhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [PubMed:11020135]
Drug created on June 13, 2005 07:24 / Updated on June 12, 2020 10:52
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","PBDB-CSI-Dry-Eye-1.jpg":"/assets/ads/PBDB-CSI-Dry-Eye-1-60c6d303827c0bb2ed5741ddc3e06aa300e9b29860b089d749ff1f943522e619.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates